Free Trial
NYSE:ALC

Alcon (ALC) Stock Price, News & Analysis

$98.11
-1.02 (-1.03%)
(As of 10/3/2024 ET)

About Alcon Stock (NYSE:ALC)

Key Stats

Today's Range
$97.87
$99.30
50-Day Range
$89.61
$100.77
52-Week Range
$69.44
$101.10
Volume
434,354 shs
Average Volume
848,583 shs
Market Capitalization
$48.38 billion
P/E Ratio
46.50
Dividend Yield
N/A
Price Target
$99.74
Consensus Rating
Moderate Buy

Company Overview

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
54th Percentile Overall Score

ALC MarketRank™: 

Alcon scored higher than 54% of companies evaluated by MarketBeat, and ranked 494th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alcon has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 13 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Alcon has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alcon's stock forecast and price target.
  • Earnings Growth

    Earnings for Alcon are expected to grow by 14.90% in the coming year, from $3.02 to $3.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alcon is 46.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alcon is 46.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.14.

  • Price to Earnings Growth Ratio

    Alcon has a PEG Ratio of 2.22. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Alcon has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Alcon's valuation and earnings.
  • Percentage of Shares Shorted

    0.67% of the float of Alcon has been sold short.
  • Short Interest Ratio / Days to Cover

    Alcon has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Alcon has recently increased by 9.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alcon does not currently pay a dividend.

  • Dividend Growth

    Alcon does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Alcon will have a dividend payout ratio of 7.49% next year. This indicates that Alcon will be able to sustain or increase its dividend.

  • Percentage of Shares Shorted

    0.67% of the float of Alcon has been sold short.
  • Short Interest Ratio / Days to Cover

    Alcon has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Alcon has recently increased by 9.03%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Alcon has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Alcon this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for ALC on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Alcon to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alcon insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.52% of the stock of Alcon is held by insiders.

  • Percentage Held by Institutions

    53.86% of the stock of Alcon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alcon's insider trading history.

ALC Stock News Headlines

NY, USA - DECEMBER 16, 2019: Homepage of bausch health website on the display of PC, url - bauschhealth.com.
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value (ALC)
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.
Time to pull back the curtain for you
Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week
Swiss Market Ends Slightly Higher
J.P. Morgan Sticks to Its Buy Rating for Gerresheimer (0NTI)
See More Headlines

ALC Stock Analysis - Frequently Asked Questions

Alcon's stock was trading at $78.12 on January 1st, 2024. Since then, ALC shares have increased by 25.6% and is now trading at $98.11.
View the best growth stocks for 2024 here
.

Alcon Inc. (NYSE:ALC) posted its quarterly earnings data on Tuesday, August, 20th. The healthcare company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. The company's revenue was up 3.3% on a year-over-year basis.

Alcon subsidiaries include Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.

Top institutional shareholders of Alcon include AMF Tjanstepension AB (0.35%), Park Avenue Securities LLC, Marotta Asset Management and SG Americas Securities LLC.

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alcon investors own include AT&T (T), Novartis (NVS), Verizon Communications (VZ), International Business Machines (IBM), Intel (INTC), Pfizer (PFE) and Cisco Systems (CSCO).

Company Calendar

Last Earnings
8/20/2024
Today
10/03/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Health Care Facilities
CUSIP
04544X30
Employees
25,000
Year Founded
1945

Price Target and Rating

Average Stock Price Target
$99.74
High Stock Price Target
$110.00
Low Stock Price Target
$85.00
Potential Upside/Downside
+1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$974 million
Pretax Margin
10.60%

Debt

Sales & Book Value

Annual Sales
$9.64 billion
Cash Flow
$5.24 per share
Book Value
$41.81 per share

Miscellaneous

Free Float
485,605,000
Market Cap
$48.30 billion
Optionable
Optionable
Beta
0.98

Social Links


This page (NYSE:ALC) was last updated on 10/3/2024 by MarketBeat.com Staff
From Our Partners